

08/900,746



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 369 409
A1

172

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 89121085.8

(51) Int. Cl.⁵: C07F 9/6512, A61K 31/675,
C07F 9/6561

(22) Date of filing: 14.11.89

(30) Priority: 14.11.88 US 270331

(43) Date of publication of application:
23.05.90 Bulletin 90/21

(54) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71) Applicant: BRISTOL-MYERS SQUIBB
COMPANY
345 Park Avenue
New York, N.Y. 10154(US)

(72) Inventor: Mansuri, Muzammil M.

1320 Deer Run Road
Cheshire Connecticut 06410(US)


Inventor: Martin, John C.
40 Brookside Place
Cheshire Connecticut 06416(US)

Inventor: Hudyma, Thomas W.
P.O. Box 245
Durham Connecticut 06422(US)


(74) Representative: Kinzebach, Werner, Dr. et al
Patentanwälte Reitzstötter, Kinzebach und
Partner Sternwartstrasse 4 Postfach 86 06 49
D-8000 München 86(DE)

(54) Carbocyclic nucleosides and nucleotides.

(57) The invention relates to 1-B-4-phosphonylmethoxycyclopentane compounds having Formula I or Formula II



I



II

wherein

R¹ and R²

are independently hydrogen, hydroxy, chlorine, bromine, or an organic substituent having 1 to 5 carbon atoms and selected from carbacyloxy, alkoxy, alkylthio, amino, alkylamino and dialkylamino,

R³ and R⁴

are independently hydrogen, or organic phosphonic ester substituents having 1 to 12 carbon atoms and selected from alkyl, alkenyl, aryl, and aralkyl,

B is a heterocyclic group having at least one nitrogen heteroatom and up to three additional heteroatoms selected from nitrogen, oxygen and sulfur, said heterocyclic group being attached through a nitrogen heteroatom thereof,

and the pharmaceutically acceptable acid addition, metal, and amine salts thereof.

These compounds are useful for treating viral diseases and diseases of microbial origin. They are also effective against infections conditions and tumors.

EP 0 369 409 A1


CARBOCYCLIC NUCLEOSIDES AND NUCLEOTIDES

FIELD OF THE INVENTION


This invention relates to carbocyclic purine and pyrimidine nucleoside analogs having a cyclopentane or cyclopentene ring instead of the deoxyribofuranose glycosidic substituent of the natural nucleosides (Class 514, Subclasses 262 and 269). The compounds are further characterized in that they have carbon-attached phosphorous-containing substituents (Class 514, Subclass 86).

SUMMARY OF THE INVENTION

The present invention relates to compounds of Formulas I and II



I



II

in which R¹ and R² are independently selected from H or OH, and substituents preparable therefrom, R³ and R⁴ are independently selected from H, alkyl, alkenyl, aryl, and aralkyl having up to 12 carbon atoms. B refers to a purine or pyrimidine base of the sort found in the natural nucleosides, attached to the cyclopentane or cyclopentene nucleus through a ring nitrogen atom thereof, and the synthetic analogs of the purine and pyrimidine bases wherein one of the ring nitrogens is replaced with carbon or one or more of the ring carbons is replaced with nitrogen, oxygen, or sulfur. There is at least one ring nitrogen atom. Formulas I and II are shown in a non-specific representation with respect to stereochemical configuration but only the cis stereochemical form relative to B and the phosphonylmethoxy group in the 4-position is intended.


The present invention includes processes for producing compounds of Formulas I and II, and certain intermediates useful in these processes.

The invention includes methods for using the compounds to treat viral diseases and diseases of microbial origin in animals * or plants, and compositions useful for these purposes. They are also effective against infectious conditions caused by other microorganisms, and against tumors in experimental animals.

BACKGROUND AND PRIOR ART

The carbocyclic analog of thymidine has been described by Shealy, et al. in J. Heterocyc. Chem 13, 1041-1047 (1976).

* (including man)



Other references disclosing purine and pyrimidine bases having respectively an N⁹- or N¹- cyclopentyl substituent of this type are disclosed in the following references.

Shealy, et al., J. Heterocyc. Chem. 18, 383-389, (1981).

Shealy, et al., J. Med. Chem. 26, 156-161 (1983).

Taniyama, et al., European Specification 236,935 published Sept. 16, 1987.


Shealy, et al., U. S. Patent No. 4,730,001 patented March 8, 1988.

Shealy, et al., U. S. Patent No. 4,396,623 patented August, 1983.


Shealy, et al., U. S. Patent NO. 4,719,214 patented Jan. 12, 1988.

The foregoing references disclose antiviral activity.

The neplanocins are antitumor antibiotics in which the ribose unit of a purine nucleoside is replaced by a substituted cyclopentene ring. Five of them have been isolated from *Ampullarilla regularis* A11079 fermentation broths. Their structures have been determined, and they have been synthesized (Hayashi, et al., J. Antibiot. 34, 675-680, (1981), Lim, et al., Tetrahedron Lett. 24, 5559-5562 (1983).




Of significance to the present invention is the synthesis of the antibiotic aristeromycin by Trost, et al., J. Am. Chem. Soc. (1988), 110, 621-622 by the following route.



Aristeromycin is a fermentation product having growth inhibitory activity against phytopathogenic bacteria and fungi (Kusaka, et al., J. Antibiotics, (1968), 21, 255). It is cytotoxic, active against murine leukemia L 1210 *in vitro*, and has antiviral activity (Herdewijn, et al., J. Med. Chem. (1985), 28, 1385-1386).



A series of 3-heterocyclo-5-hydroxymethylcyclopentanols having strong antiviral activity against Herpes simplex virus 2, strain G is disclosed in U. S. Patent No. 4,605,659 of Verheyden, et al., patented Aug. 12, 1986.

Another group of antiviral nucleoside compounds is typified by the phosphonomethoxyadenine derivatives typified by (S)-HPMPA which has the following formula (Holy, et al., Nucleic Acids Research, Symposium Series No. 14, 1984, pages 277-278, and UK specification 2,134,907, published Aug. 22, 1984).



DETAILED DESCRIPTION OF THE INVENTION

This invention refers to compounds of Formulas I and II, to methods for their synthesis, to the method of treating infections of viral or microbial origin in animals or plants by the administration of these compounds to the host organism, and to compositions useful for the latter purpose.



In Formulas I and II, the symbols B, R¹, R², R³, and R⁴, have the following meanings. R¹ and R² are independently hydrogen, hydroxy, chlorine, bromine, amino, or an organic substituent having 1 to 5 carbon atoms and selected from acyloxy, alkoxy, alkylthio, alkylamino, and dialkylamino. The latter contain from 1 to 12 carbon atoms. R³ and R⁴ are independently hydrogen, or an organic substituent having 1 to 12 carbon atoms and selected from alkyl, alkenyl, aryl, and aralkyl. B is a heterocyclic group having at least one nitrogen heteroatom and up to three additional heteroatoms selected from nitrogen, oxygen and sulfur, said heterocyclic group being connected through a nitrogen heteroatom thereof, and the metal and amine salts of those compounds of Formulas I and II wherein at least one of R³ and R⁴ is hydrogen.

The salts just alluded to are considered part of the present invention. Those salts which are pharmaceutically acceptable are of particular interest since they are useful in administering the foregoing compounds for medical purposes. Some salts which are not pharmaceutically acceptable are useful in manufacturing processes, for isolation and purification purposes, and in some instances, for use in separating stereoisomeric forms of the compounds of Formulas I and II. The latter is particularly true of amine salts prepared from optically active amines.

Pharmaceutically acceptable metal and amine salts are those salts which are stable under ambient conditions, and wherein the cation does not contribute significantly to the toxicity or biological activity of the salt. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, and aluminium salts. The sodium and potassium salts are preferred. Suitable amine salts are prepared from amines which have sufficient basicity to form a stable salt, and preferably include those amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use. These include the trialkylamines such as triethylamine, and others including procaine, dibenzylamine, N-benzyl-beta-phenethylamine, ephedrine, and N,N'-dibenzylethylenediamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, and dicyclohexylamine.

Those compounds of Formulas I and II in which R¹ or R² is a basic function such as the amino, alkylamino, or dialkylamino group or if such group is present as a substituent on B, R¹, or R², will form acid addition salts. Again, such salts are intended to be included in the present invention. As before, the pharmaceutically acceptable acid addition salts are preferred. They are the acid addition salts in which the anion does not contribute significantly to the toxicity of the salt, and which salts are compatible with the customary pharmaceutical vehicles and adapted for oral or parenteral administration to animals or for application to plants. Some suitable acids for use in the preparation of such salts are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, various organic carboxylic and sulfonic acids such as acetic acid, citric acid, propionic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid, malic acid, methanesulfonic acid, toluenesulfonic acid, and others.

DOSAGE AND ADMINISTRATION

The present substances have utility as antiviral, antimicrobial, and antitumor agents. Their antiviral properties can be measured and demonstrated by any of a variety of laboratory methods which are available for this purpose. Similarly, utility against plant pathogens and microbial infections caused by bacteria and other microorganisms can be demonstrated by methods which are well known to those skilled in the art. Their antitumor activity can be shown by established techniques in animals bearing experimental tumors or *in vitro* by using various animal and human tumors. The particular spectrum of viruses and microorganisms against which the present substances are active varies from compound to compound. The murine leukemia virus is an example of a retrovirus which is sensitive to the present compounds. A number of disease conditions including AIDS are caused by retroviruses. The test method is given below and results for several compounds are presented in Table I.

TESTING AND EVALUATING OF COMPOUNDS AGAINST MURINE RETROVIRUSES.

The compounds were evaluated for antiviral activity against Murine leukemia virus (MuLV) strains using the UV-XC plaque assay (Rowe, et al., "Virology," 42:1136, 1970).

The MuLV strains were grown in feral mouse cells (SC-1) and used for antiviral tests using the UV-XC plaque assay. Briefly, SC-1 cells are grown as monolayers in 4-well tissue culture plates and inoculated with approximately 50-100 plaque forming units of MuLV in 0.5 ml of 5% EMEM (Earle's Minimum Essential Medium) containing 20 mcg/ml-DEAE/Dextran. After 1 hr. adsorption, the inoculum is removed and 5 ml of 5% EMEM containing three-fold dilutions of the appropriate drug are added. Five days later, the cultures are UV irradiated with an ultraviolet lamp and rat XC sarcoma cells are added to the cultures. Three or four days after UV-irradiation, the cell cultures are stained with Giemsa stain and the plaques are counted. Antiviral activity is expressed in terms of the reduction in the mean number of UV-XC plaques counted in the drug treated, virus-infected cultures compared with mean number of plaques counted in untreated, virus-infected control cultures, and reported as ID₅₀ (mcg/ml). The ID₅₀ is the concentration of test substance in the medium which reduces the number of plaques formed by 50%. It is usually determined by interpolation from a concentration response graph prepared after testing several multiple concentrations.

Table I

In Vitro Murine Leukemia Virus ID₅₀

Compound No. ²	Formula	Structure ¹			toxicity ID ₅₀		
		R ³	R ⁴	Virus	(mcg/ml)	(mcg/ml)	Index
AZT ³	not applicable			Maloney	-	0.001	-
40445	I	C ₂ H ₅	C ₂ H ₅	Maloney	32	4.68	6.8
40803	I	H	H	Maloney	>32	>1	>32
40815	II	C ₂ H ₅	C ₂ H ₅	Maloney	32	7.69	4.2
40815	II	C ₂ H ₅	C ₂ H ₅	Rauscher	>32	10.5	>3.0
40843	II	H	H	Maloney	>32	4.88	>6.6
40843	II	H	H	Maloney	>32	3.29	>9.7

³ AZT is a commercial anti-viral agent, non-proprietary name zidovudine, 3'-azido-3'-deoxythymidine.

¹ B in Formula I and Formula II is 9-adeninyl; R¹ and R² of Formula II are each H.

² Preparative procedures are found in the examples numbered as follows:

40445	Example V
40803	Example EE
40815	Example FF
40843	Example GG

Pharmaceutical compositions, both veterinary and human, containing the claimed compounds which are appropriate for antiviral use are prepared by methods and contain excipients which are well known in the art. A generally recognized compendium of such methods and ingredients is Remington's Pharmaceutical Sciences by E. W. Martin, (Mark Publ. Co., 15th Ed., 1975).

The compounds of the invention may be administered parenterally (for example, by intravenous, subcutaneous, intraperitoneal, or intramuscular injection), orally, topically, intranasally, or rectally.

The compositions are administered orally or parenterally at dose levels of about 0.1 to 300 mg/kg of compound of Formula I or compound of Formula II, preferably 1.0 to 30 mg/kg of body weight. Unit dosage forms administered one to five times daily in the amount of 10 to 500 mg per unit dose, are contemplated for man.

For parenteral administration or for administration as drops, as for eye infections, the compounds may be presented in aqueous solution in a concentration of from about 0.1 to 10%, more preferably about 0.1 to 7%. The solution may contain antioxidants, buffers, and other suitable additives.

Alternatively for infections of the eye, or other external tissues, e.g. mouth and skin, the compositions are preferably applied to the infected part of the body of the patient topically as an ointment, cream, aerosol

or powder, preferably as an ointment or cream. The compounds may be presented in an ointment, for instance with a water soluble ointment base, or in a cream, for instance with an oil in water cream base, in a concentration of from about 0.01 to 10%.


The compounds of the present invention or compositions containing them are also useful in treating non-human mammals, bird, eg., chickens and turkeys, and cold-blooded animals, e.g., fish.

Fish which are in a confined area such as a pool, aquarium, or holding tank may also be treated for viral infections such as herpes-like viruses, e.g., channel catfish virus (CCV), herpes-virus salomones, Nerka virus and the like by adding the compound directly to the water of the pool, aquarium, or holding tank or by incorporating the compounds into the feed.


The exact regimen for administration of the compounds and compositions disclosed herein will necessarily be dependent upon the needs of the individual subject being treated, the type of treatment and, of course, the judgment of the attending physician.

PREPARATIVE METHODS

The phosphonic esters of Formula I wherein R^3 and R^4 as defined, but other than hydrogen, are useful end products and also organic phosphonic ester substituents are key intermediates for the preparation of the other compounds of the present invention. Considering the cyclopentene ring as the central nucleus of these compounds they are prepared by either of two sequences. According to the preferred sequence the purine or pyrimidine base substituent B is first introduced to provide a cis-4-hydroxycyclopent-2-en-1-yl derivative of Formula IV. The cyclopentenol of Formula IV is then etherified by treatment with a phosphonyl methylating agent of Formula V in which L is a leaving group. The preferred phosphonylmethylating agent is diethyl phosphonylmethyltrifluoromethane sulfonate (Kluge, Organic Synthesis (1985), 64 80). When operating on a pyrimidine base, the use of protecting groups for the ring nitrogen atom in the 3 position or 4-amino substituent when present is sometimes desirable. Whether or not this expedient is required in a given instance is readily determined by the skilled chemist by carrying out trial reactions on a small scale.




Alternatively the phosphonylmethyl ether group may be introduced first to provide a 1,4 disubstituted cyclopent-2-ene of Formula VI, where L is a leaving group in the trans-configuration.



Again, the leaving group L is of a similar nature as with respect to Formula V and may include halogen, alkylsulfonate or arylsulfinate.

The method of Trost, et al. cited above, J. Med. Chem. Soc. (1988), 110, 621-622 involving reaction of adenine with 3,4-epoxycyclopent-2-ene under the control of palladium (0) has proven to be suitable for the preparation of the Formula IV intermediates for the preferred sequence outlined above. The reaction proceeds in good yield, and produces the desired 1 β ,4 β cyclopent-2-ene nucleoside analog stereoselectively. The intermediates of Formula VI required for the alternate route may be prepared from 3,4-epoxycyclopent-2-ene which on reaction with thiophenol in the presence of triethylamine (D. A. Evans, et

al., J. Org. Chem. 1976, 39, 3178) yields trans-1-hydroxy-2-phenylthiocyclopent-3-ene. This may be etherified with diethoxyphosphonylmethyl trifluoromethanesulfonate as described above. Oxidation of the phenyl sulfide to the sulfoxide and rearrangement and hydrolysis yields the monoetherified transcyclopent-2-ene-1,4-diol of Formula VII



Formula VII

The leaving group L of Formula VI is conveniently an alkyl- or arylsulfinate obtained by reaction of the compound of Formula VII with phenylsulfinyl chloride (or other arylsulfinyl chloride) or an alkylsulfinyl chloride. The alkylsulfonates or arylsulfonates so produced are then converted to the compounds of Formula I by suitable displacement reactions. Those compounds of Formula VI wherein L is chlorine can be heated with the sodium salt form of the chosen heterocycle B in the presence of sodium bromide or sodium iodide to yield the desired cis-1,4-substituted products of Formula I.

According to a further alternate method the monoetherified trans-dial of Formula VII may be converted directly to products of Formula I by means of a Mitsunobu reaction (O. Mitsunobu, Synthesis 1981, 1) in which the heterocyclic base B acts as the nucleophile.

The compound of Formula I is then transformed into a compound of Formula II according to any of a number of well established techniques in organic chemistry. For example, catalytic hydrogenation of a compound of Formula I yields a compound of Formula II in which R¹ and R² are hydrogen atoms. Another technique that may be used is hydroxylation. Hydroxylation with osmium tetroxide and N-methylmorpholine-N-oxide according to Van Rhee, et al., Tetrahedron Letters, 1976, 1973 yield the dehydroxy compound (R¹ and R² are each OH). Hydroboration yields a mixture of monohydroxy compounds which can be separated (one of R¹ and R² is OH and the other is H). The resulting hydroxy compounds can then be converted to various derivatives of the hydroxyl group such as the acyloxy, alkoxy, alkylthio, halogen, amino, alkylamino and dialkylamino groups by methods available in the art.

The di-esters of Formula I and Formula II may be hydrolyzed to the corresponding monoesters, wherein one of R³ and R⁴ is a hydrogen atom and the other is an organic phosphonic ester substituent as before. Hydrolysis may be carried out with aqueous sodium hydroxide solution at room temperature to yield the monoester. The dibasic acid of Formula I or Formula II is prepared by cleavage of the corresponding mono or diester with trimethylsilyl bromide. This reaction is carried out in the absence of water using dimethylformamide or acetonitrile as solvent. Room temperature and protection of the reaction mixture from the atmosphere are preferred conditions.

Description of Specific Embodiments	
Abbreviations Used	
THF	tetrahydrofuran
SEM-Cl	2-(trimethylsilyl)ethoxymethyl chloride
HPLC	high performance liquid chromatography
rt	room temperature
HOAc	acetic acid
mCPBA	m-chloroperbenzoic acid
DMF	dimethylformamide
IPA	isopropyl alcohol
EtOAc	ethyl acetate

EXAMPLE A: (±)-9-(4-β-Hydroxycyclopent-2-ene-1-β-yl)adenine

A solution of 3,4-epoxycyclopentene (194 mg, 2.36 mmol) in DMF (1.5 mL) was added dropwise over two mins to a stirred mixture of adenine (319 mg, 2.36 mmol) and tetrakis(triphenylphosphine)palladium (0) (137 mg, 0.118 mmol) in DMF (5 mL) and THF (2 mL) at 22 °C under argon. There was a mild exotherm after which the reaction was stirred for 1 hr at ambient temperatures and then for 2 hrs at an oil bath temperature of 80-90 °C. The mixture was then poured into warm water and filtered. After an additional filtration through a 0.45 µm nylon membrane filter the filtrate was pumped onto a Michel-Miller (310 x 25 mm) column which packed with Partisil Prep 40TM ODS-3. The column was eluted with 0.025 M of pH5 ammonium phosphate buffer containing 4-10% CH₃CN. The progress of elution was monitored with a refractive index detector and the appropriate fractions were combined. The pH of the combined eluates was adjusted to 7.06 with dilute NaOH. The resulting solution was concentrated and the residue was dissolved in H₂O (20 mL). The solution was applied to the Michel-Miller column and the column eluted with H₂O (200 mL) to remove the inorganic salts. Elution with H₂O-10% CH₃CN afforded the title compound, which was isolated as a colorless powder (170 mg, 33%) after removal of the CH₃CN followed by lyophilization of the resulting aqueous solution. Analysis: C₁₀H₁₁N₅O 0.25H₂O: (calc) C: 54.17, H: 5.02, N: 31.59, H₂O, 2.03; (found) C: 54.12, H: 5.27, N: 31.07, H₂O, 1.77. ¹H NMR (360 MHz, D₂O) δ 8.03 (s, 1H), 8.00 (s, 1H), 6.25 (m, 1H), 6.06 (m, 1H), 5.36 (m, 1H), 4.85 (m, 1H under HDO resonance), 3.01 (m, 1H), 1.71 (m, 1H).

20 EXAMPLE B: (±)-1-(4-β-Hydroxycyclopent-2-ene-1-β-yl)thymine

A solution of 3,4-epoxycyclopentene (361 mg, 4.39 mmol) in DMF (1 mL) was rapidly added to a stirred, deoxygenated mixture of thymine (462 mg, 3.66 mmol) and tetrakis(triphenylphosphine)palladium (0) (212 mg, 0.183 mmol) in a mixture of DMF (5 mL) and THF (2 mL) at 22 °C under argon. The reaction mixture was then stirred at 90 °C for 1 hr. The mixture was cooled and filtered. The filtrate was diluted with H₂O and concentrated to a volume of about 20 mL. The hazy solution was refiltered (0.45 µm membrane) and chromatographed and desalted on the Michel-Miller C18 column as described in the previous example to provide an aqueous solution of the title compound. The solution was concentrated on a rotary evaporator to a volume of about 5 mL, whereupon colorless crystals (121 mg, 16%) of the analytical sample were formed. M.p. 197 - 198 °C. Analysis: C₁₀H₁₂N₂O₃ (calc.) C: 57.69, H: 5.81, N: 13.45; (found) C: 57.39, H: 5.90, N: 13.38. ¹H NMR (360 MHz, D₂O) δ 7.38 (s, 1H), 6.20 (m, 1H), 5.88 (m, 1H), 5.41 (m, 1H), 4.83 (m, 1H), 2.94 (m, 1H), 1.84 (s, 3H), 1.45 (m, 1H).

(±)-1-(4-β-Hydroxycyclopent-2-ene-1-β-yl)thymine was isolated in a comparable yield when the tetrakis(triphenylphosphine) palladium (0) catalyst was replaced with Pd[P(*i*-OC₃H₇)₃]₄ as the palladium (0) catalyst in the above experiment.

The isolated yield of (±)-1-(4-β-Hydroxy-2-cyclopenten-1-β-yl)thymine was 36% when a solution of 3,4-epoxycyclopentene (4.61 g, 56.1 mmol) in DMF (7 mL) was added dropwise over 40 minutes to a stirred, deoxygenated mixture of thymine (4.4g, 34.6 mmol) and tetrakis(triphenylphosphine)palladium (0) (2.0 g, 1.73 mmol) in DMF (60 mL) at an oil bath temperature of 90 °C. Stirring was continued at 90 °C for 3.25 hrs and the title compound isolated and purified by chromatography on a Michel-Miller column (40x350mm) as previously described.

45 EXAMPLE C: (±)-1-(4-β-Hydroxycyclopent-2-ene-1-β-yl) cytosine.

A solution of 3,4-epoxycyclopentene (272 mg, 3.31 mmol) in DMF (1 mL) was rapidly added to a stirred, deoxygenated mixture of cytosine (307 mg, 2.76 mmol) and tetrakis(triphenylphosphine)palladium (0) (160 mg, 0.138 mmol) in THF (2 mL) and DMF (5 mL) at 22 °C. An immediate mild exothermic reaction ensued. The reaction mixture was stirred for 72 hrs at ambient temperature. The mixture was filtered and the filtrate was diluted with H₂O. The hazy filtrate was refiltered (0.45mm nylon membrane) and the clarified solution pumped onto the Michel-Miller (310 x 25 mm) C₁₈ column. The column was eluted with 0.025 M of pH 4.8 ammonium phosphate buffer containing 5% CH₃CN, and the progress of elution monitored by differential refractometry. The pH of the appropriately combined eluates was adjusted to 7.2 with dilute NH₄OH. The volume of the combined eluates was reduced to about 4 mL on a rotary evaporator. The solution was applied to the Michel-Miller C₁₈ column. The column was eluted with H₂O to remove the inorganic material and then with H₂O-10% CH₃CN to elute the title compound as a colorless solid (54 mg, 10.1 %) which was isolated by lyophilization. Analysis: C₉H₁₁N₃O₂ (calc) C: 55.98, H: 5.74, N: 21.75;

(found) C: 55.25, H: 5.87, N: 21.48. ¹H NMR (360 MHz, D₂O) δ 7.53 (d, 1H), 6.20 (m, 1H), 6.00 (d, 1H), 5.90 (m, 1H), 5.41 (m, 1H), 4.79 (m, 1H under HDO resonance), 2.96 (m, 1H), 1.41 (m, 1H).

In an improved procedure, (±)-1-(4-β-hydroxycyclopent-2-ene-1-β-yl)cytosine was isolated in a lyophilized yield of 54% when a solution of 3,4-epoxycyclopentene (790 mg, 9.62 mmol) in DMF (1.5 mL) was added dropwise over 1.25 hrs to a stirred, deoxygenated mixture of cytosine (754 mg, 6.78 mmol), tetrakis-(triphenylphosphine) palladium (0) (413 mg, 0.357 mmol) and triphenylphosphine (187 mg, 0.714 mmol) in DMF (15 mL) at 22 °C. The mixture was then stirred at 22 °C for 0.66 hrs, 50 °C for 0.6 hrs and then at 80 °C for 0.25 hrs, the title compound was isolated as described above.

EXAMPLE D: (±)-1-(4-β-Hydroxycyclopent-2-ene-1-β-yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine.

Method 1.

A mineral oil dispersion of 50% NaH (18 mg, 0.378 mmol) was added to a stirred mixture of (±)-1-(4-β-hydroxycyclopent-2-ene-1-β-yl)thymine (75 mg, 0.36 mmol) in DMF (0.5 mL) at 22 °C. After the rapid evolution of hydrogen subsided, the mixture was stirred at 60 °C for 5 mins to complete salt formation. The mixture was cooled in a IPA/CO₂ bath to -40 °C to -30 °C, a solution of 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) (61 mg, 0.36 mmol) in DMF (0.5 mL) was then added dropwise over 8 mins. Stirring was continued with cooling for 0.25 hrs and then at 22 °C for 0.66 hrs. The mixture was concentrated and the residue partitioned between EtOAc and H₂O. The EtOAc layer was washed (H₂O, brine), dried (Na₂SO₄) and concentrated. The residue was chromatographed on SiO₂ (10 g) with CH₂Cl₂-acetone (20:3) to afford the title compound (65 mg, 53% yield) as a viscous oil with an estimated purity of 93.4 % by HPLC.

HPLC: rt 5.88 mins (Waters C₁₈ radial pak cartridge) flow rate 2 mL/min of 45% pump A (90% H₂O-10% CH₃CN), 55% pump B (20% H₂O-80% CH₃CN). Detection at 254 nm. ¹H NMR (200 MHz, CDCl₃) δ 7.16 (s, 1H), 6.20 (m, 1H), 5.82 (m, 1H), 5.52 (m, 1H), 5.41 (s, 2H), 4.86 (m, 1H), 3.69 (m, 2H), 2.90 (m, 1H), 2.70 (bs, 1H), 1.92 (s, 3H), 1.61 (m, 1H), 0.98 (m, 2H), 0.02 (s, 9H).

Method 2.

A solution of (±)-1-(4-β-acetoxycyclopent-2-en-1-β-yl)-N³-(2-(trimethylsilyl)ethoxymethyl)thymine (2.26 g, 5.94 mmol) in CH₃OH (75 mL) was saturated with NH₃ at 10 °C. The solution was allowed to stand for 20 hrs at ambient temperatures and then was concentrated. The residue was partitioned between Et₂O and H₂O. The ethereal layer was washed with H₂O, followed by brine and then dried over Na₂SO₄. Removal of the ether afforded the title compound (2.0 g, 99.5%) which was identical to that prepared in Method 1.

EXAMPLE E: (±)-1-(4-β-Acetoxycyclopent-2-ene-1-β-yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine and (±)-1-(4-β-Hydroxycyclopent-2-ene-1-β-yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine.

A mineral oil dispersion of 50% NaH (0.608 g, 12.7 mmol) was added to a cooled (ice/H₂O bath), stirred mixture of (±)-1-(4-β-hydroxycyclopent-2-ene-1-β-yl)thymine (2.51 g, 12.1 mmol) in DMF (17 mL) under argon. The cooling bath was removed after the vigorous evolution of hydrogen subsided and stirring was continued at ambient temperatures for 0.25 hrs, and then for an additional 0.25 hrs at 50 °C on a steam bath. The stirred mixture was cooled in a IPA/CO₂ bath which was maintained at -40 °C. A solution of SEM-Cl (2.01 g, 12.1 mmol) in DMF (17 mL) was added dropwise during 5 mins. Stirring was continued with cooling for 0.25 hrs at -40 °C and then 0.5 hrs at ambient temperatures. The mixture was concentrated and the residue partitioned between EtOAc and H₂O. The EtOAc layer was washed (H₂O, brine), dried (Na₂SO₄) and concentrated. The residue was flash chromatographed on SiO₂ (150 g) with CH₂Cl₂-acetone (100:15) to provide (±)-1-(4-β-hydroxycyclopent-2-ene-1-β-yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine (790 mg, 19% yield) as a viscous oil and (±)-1-(4-β-acetoxycyclopent-2-ene-1-β-yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine (3.1 g, 68%). Recrystallization of the latter compound from hexane afforded colorless crystals of the analytical sample. M.p. 65-66 °C. Analysis C₁₈H₂₈N₂O₅Si (calc) C: 56.82, H: 7.42, N: 7.37; (found) C: 56.59, H: 7.42, N: 7.29.

¹H NMR (200 MHz, CDCl₃) δ 7.00 (s, 1H), 6.23 (m, 1H), 5.93 (m, 1H), 5.70 (m, 2H), 5.38 (s, 2H), 3.70 (m, 2H), 3.00 (m, 1H), 2.09 (s, 3H), 1.94 (s, 3H), 1.65 (m, 1H), 0.99 (m, 2H), 0.01 (s, 9H).

EXAMPLE F: (\pm) -1-(4- β -Diethylphosphonylmethoxycyclopent-2-ene-1- β -yl)-N3-(2-(trimethylsilyl)ethoxymethyl) thymine.

5 Method 1.

A mineral oil dispersion of 50% NaH (10.4 mg, 0.217 mmol) was added to a stirred solution of (\pm) -1-(4- β -hydroxycyclopent-2-ene-1- β -yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine (70 mg, 0.207 mmol) in DMF (0.5 mL) at 22 °C. Stirring was continued for 0.5 hrs at 22 °C and then for 0.25 hrs at 60 °C. The solution
 10 was cooled in an IPA/CO₂ bath maintained at -40 °C when a solution of diethyl phosphonomethyltrifluoromethane sulfonate (68.3 mg, 0.23 mmol) in DMF (0.5 mL) was added dropwise over 4 mins. Stirring was continued with cooling for 0.25 hrs and then at ambient temperature for 0.66 hrs. The mixture was concentrated and the residue partitioned between EtOAc and H₂O. The ethyl acetate layer was washed (H₂O, brine), dried (Na₂SO₄) and concentrated to leave a brown oil. The oil was chromatographed on SiO₂ -
 15 (10 g) with CH₂Cl₂-acetone (200:25) to afford the title compound (25 mg, 25 %) as a viscous oil, with an estimated purity of 92% (HPLC). HPLC : rt 10.47 minutes (Waters C₁₈ radial pak cartridge) flow rate 2mL/min; 45% pump A (90%H₂O-10%CH₃CN), 55% pump B (20%H₂O-80%CH₃CN). Detection at 254 nm. ¹H NMR (200 MHz, CDCl₃) δ 7.19 (s, 1H), 6.19 (m, 1H), 5.95 (m, 1H), 5.76 (m, 1H), 5.48 (s, 2H), 4.65 (m, 1H), 4.23 (m, 4H), 3.92 (m, 2H), 3.76 (m, 2H), 2.92 (m, 1H), 1.99 (s, 3H), 1.74 (m, 1H), 1.45 (m, 6H), 1.07
 20 (m, 2H), 0.06 (s, 9H).

Method 2:

25 A solution of 2.5 M n-BuLi in hexane (2.7 mL, 6.75 mmol) was added dropwise to a cooled (CO₂/acetone bath) stirred solution of (\pm) -1-(4- β -hydroxycyclopent-2-ene-1- β -yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine (1.9 g, 5.61 mmol) in THF (15 mL) under argon. A solution of diethyl phosphonylmethyltrifluoromethane sulfonate (2.53 g, 8.41 mmol) in THF (2 mL) was added dropwise over 1 min. The reaction was stirred at approximately -70 °C for 0.25 hrs and then the solution was allowed to warm to 22
 30 °C. The solution was cooled in an ice/salt bath mixture and stirred for a further 0.25 hrs. Saturated aqueous NH₄Cl was added and the THF removed in vacuo. The aqueous mixture was extracted with EtOAc and the organic layer sequentially washed (dilute aqueous NaHCO₃, H₂O, brine) and dried (Na₂SO₄). Removal of the EtOAc left a brown oil (3 g) which was flash chromatographed on SiO₂ (120 g) with CH₂Cl₂-acetone (10:1) to afford an initial fraction (877 mgs) containing the title compound with an estimated purity of 88 %
 35 by HPLC and an additional fraction of 494 mgs containing the title compound with an estimated purity of 73 % by HPLC. The major contaminant was the starting alcohol.

EXAMPLE G: (\pm) -1-(4- β -Phosphonylmethoxycyclopent-2-ene-1- β -yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine.

Bromotrimethylsilane (1.3 mL, 9.67 mmol) was added dropwise over 1 min to a stirred solution of (\pm) -1-(4- β -diethylphosphonylmethoxycyclopent-2-ene-1- β -yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine (315 mg, 0.645 mmol) in DMF (5 mL) at 22 °C and under argon. The solution was stirred at ambient temperature for
 45 4 hrs and then was concentrated to dryness in vacuo. The residual brown oil was dissolved in DMF (5 mL) and the solution reconcentrated. A solution of the residue in H₂O was applied to the Michel-Miller C₁₈ column. The column was eluted with H₂O containing from 10 to 40% of CH₃CN. The appropriate eluates were combined and concentrated to leave the title compound (144 mg, 74%) as a viscous glass. ¹H NMR (200 MHz, CDCl₃) δ 7.20 (s, 1H), 6.23 (m, 1H), 5.93 (m, 1H), 5.66 (m, 1H), 5.41 (s, 2H), 4.59 (m, 1H), 3.85
 50 (m, 2H), 3.73 (m, 2H), 2.80 (m, 1H), 1.93 (s, 3H), 1.78 (m, 1H), 1.00 (m, 2H), 0.02 (s, 9H).

EXAMPLE H: (\pm) -1-(4- β -Phosphonylmethoxycyclopent-2-ene-1- β -yl)thymine and (\pm) -1-(4- β -phosphonylmethoxycyclopent-2-ene-1- β -yl)-N3-(hydroxymethyl)thymine.

55 Bromotrimethylsilane (2.0 mL) was added dropwise to a stirred solution of (\pm) -1-(4- β -diethylphosphonomethoxycyclopent-2-ene-1- β -yl)-N3-(2-(trimethylsilyl)ethoxymethyl)thymine (494 mg, estimated purity of 73%) in DMF (5 mL) at 22 °C and under argon. The solution was stirred for 0.25 hrs and

then was concentrated to dryness. The residue was dissolved in a mixture of EtOH (18 mL) and 1N HCl (18 mL). The mixture was stirred at an oil bath temperature of 55 °C for 0.75 hrs and then was heated to reflux for 1 hr. The solution was concentrated and the residue dissolved in H₂O. The aqueous solution was washed with ether and concentrated. The concentrate was applied to the Michel-Miller C₁₈ column. The column was eluted with H₂O containing 3% CH₃CN. Two groups of eluates were combined and the CH₃CN removed by concentration in vacuo. Removal of the H₂O from each group by lyophilization provided (±)-1-(4,β-phosphonomethoxycyclopent-2-ene-1-β-yl)thymine as a colorless solid (25 mg). HPLC: rt 6.93 mins (Waters C₁₈ radial pak cartridge) flow rate 2mL/min 95% pump A (0.05 M of pH 4.3 ammonium phosphate buffer), 5% pump B(20% H₂O-80% CH₃CN). Detection at 254 nm. ¹H NMR (360 MHz, DMSO-D₆) δ 11.25 (s, 1H), 7.20 (s, 1H), 6.32 (m, 1H), 5.94 (m, 1H), 5.42 (m, 1H), 4.51 (m, 1H), 3.59 (m, 1H), 2.66 (m, 1H), 1.74 (s, 3H), 1.58 (m, 1H), and a mixture of the foregoing and (±)-1-(4-β-phosphonylmethoxycyclopent-2-ene-1-β-yl)-N3-(hydroxymethyl)thymine (25.8 mg). HPLC: rt 11.06 min containing 33% of the fully deprotected thymine derivative. The pH of an aqueous solution of this latter mixture was raised to 12, which removed the N³ hydroxymethyl group.

EXAMPLE I: (±)-1-(4-β-Phosphonomethoxycyclopent-2-ene-1-β-yl)thymine.

Bromotrimethylsilane (3.6 mL) was added dropwise to a stirred solution of (±)-1-(4,β-diethylphosphonomethoxycyclopent-2-ene-1-β-yl)-N3-2-(trimethylsilyl)ethoxymethylthymine (860 mgs) in DMF (10 mL) at 22 °C and under argon. The solution was stirred for 2.5 hrs and concentrated. The residue was diluted with DMF and re-concentrated. A mixture of the residue in EtOH (25 mL) and 1 N HCl (25 mL) was heated to reflux for 1.5 hrs. The mixture was concentrated to dryness and the residue dissolved in H₂O (5 mL). The pH of the solution was raised to 12.8 by the addition of 1 N NaOH. After several minutes the pH was lowered to 2.2 by the addition of 85% H₃PO₄. The solution was applied to the Michel-Miller C₁₈ column. The column was eluted with a mixture of H₂O-CH₃CN-HOAc (1000:40:3). The appropriate fractions were combined as determined by HPLC and concentrated to dryness. The residue was dissolved in H₂O and the aqueous solution concentrated by lyophilization to afford the title compound as a colorless lyophilate. This lyophilate was combined with several others from previous small scale experiments and the combination recrystallized from H₂O (1 mL) to afford colorless crystals of the title compound (56 mg). M. p. 116-118 °C.

Analysis: C₁₁H₁₅N₂O₅P.H₂O (calc) C: 41.26, H: 5.35, N: 8.74; (found) C: 41.36, H: 5.03, N: 8.85.

EXAMPLE J: (±)-1-(4-β-Hydroxycyclopent-2-ene-1-β-yl)-N4-(dimethylaminomethylidene) cytosine.

N,N-Dimethylformamide dimethyl acetal (361 μL, 2.72 mmol) was added to a stirred mixture of (±)-1-(4-β-hydroxycyclopent-2-ene-1-β-yl)cytosine (500 mg, 2.59 mmol) in DMF (10 mL). The reaction was then heated for 1.5 hrs at an oil bath temperature of 70-80 °C, during which time solution occurred. The solution was concentrated and the residual solid crystallized from CH₂Cl₂ with the addition of ether to provide peach crystals of the title compound (580 mg, 90%). M. p. 180-181 °C. Analysis: C₁₂H₁₆N₄O₂ (calc) C: 58.06, H: 6.50, N: 22.57; (found) C: 57.62, H: 6.47, N: 22.18. ¹H NMR (200 MHz, d₆ DMSO) δ 8.63 (s, 1H), 7.63 (d, 1H), 6.15 (m, 1H), 6.00 (d, 1H), 5.80 (m, 1H), 5.50 (m, 1H), 5.25 (m, 1H, exchangeable), 4.69 (m, 1H), 3.19 (s, 3H), 3.03 (s, 3H), 2.96 (m, 1H), 1.35 (m, 1H).

EXAMPLE K: (±)-1-(4-β-Diethylphosphonomethoxycyclopent-2-ene-1-β-yl)-N4-(dimethylaminomethylidene) cytosine.

A solution of 2.5 M n-BuLi in hexane (0.8 mL, 2.01 mmol) was added dropwise to a stirred mixture of (±)-1-(4-β-hydroxycyclopent-2-ene-1-β-yl)-N4-(dimethylaminomethylidene) cytosine (500 mg, 2.01 mmol) in HMPT (3 mL) and THF (4 mL) which was cooled in a IPA/CO₂ bath maintained at -40 to -30 °C. Stirring was continued at -40 to -20 °C for 0.5 hrs. The solution was then cooled to -40 °C when a solution of diethylphosphonomethyltrifluoromethane sulfonate (755 mg, 2.52 mmol) in THF (2 mL) was added dropwise. The solution was allowed to warm to 22 °C during 1.5 hrs and was quenched by the addition of saturated aqueous NH₄Cl (1 mL). The mixture was concentrated and the concentrate, which contained residual HMPT, was flash column chromatographed. The column was sequentially eluted with CH₂Cl₂ (200 mL) and then with CH₂Cl₂ containing 10% MeOH to afford the title compound (1.1 g) as a gum, with an estimated

purity of 90.6% by HPLC. HPLC: rt 4.87 mins (Waters C₁₈ radial pak cartridge); flow rate 2mL/min. of 75% pump A (0.05 M of pH 5 ammonium phosphate buffer), 25% pump B (20% H₂O-80% CH₃CN).

5 **EXAMPLE L: (±)-1-(4-β-Phosphonomethoxycyclopent-2-ene-1,β-yl) cytosine.**

Bromotrimethylsilane (1.7 mL, 12.6 mmol) was added to a stirred solution of (±)-1-(4-β-diethylphosphonomethoxycyclopent-2-ene-1-β-yl)-N4-(dimethylaminomethylidene)cytosine (1 g, 2.51 mmol) in DMF (5 mL) at 22 °C. The reaction was stirred for two hours and then concentrated to dryness. A solution of residue in H₂O was applied to the Michel-Miller C₁₈ column. The column was eluted with 0.025 M of pH 5 ammonium phosphate buffer containing 2% CH₃CN. The appropriate eluates were combined and the CH₃CN removed in vacuo. The aqueous solution was lyophilized and the residual solid was dissolved in water and the solution applied to the Michel-Miller C₁₈ column. The column was eluted with H₂O to remove the inorganic salts. Elution with H₂O containing 20% CH₃CN provided the title compound (166mg, 23%) as a colorless lyophilate with an estimated purity of >99% by HPLC. HPLC: rt 5.49 mins (Waters C₁₈ radial pak cartridge); flow rate 2mL/min of 98% pump A (0.05 M of pH 5 ammonium phosphate buffer), 2% pump B (20% H₂O-80%CH₃CN). Detection at 254 nm. Crystallization from H₂O-EtOH provided the analytical sample. M. p. 238-240 °C (decomp). Analysis C₁₀H₁₄N₃O₅P (calc) C: 41.83, H: 4.92, N: 14.64; (found) C: 41.19, H: 4.95, N: 14.52.

20 ¹H NMR (360 MHz, d₆ DMSO) δ 7.35 (d, 1H), 6.27 (d, 1H), 5.91 (d, 1H), 5.69 (d,1H), 5.50 (m, 1H), 4.52 (m, 1H), 3.56 (d, 2H), 2.67 (m, 1H), 1.44(m,1H).

EXAMPLE M: (±)-1-(4-β-Phosphonomethoxycyclopentane-1-β-yl)cytosine.

25 A mixture of (±)-1-(4-β-phosphonomethoxycyclopent-2-ene-1-β-yl)cytosine (20 mg) and 10% palladium on carbon (15 mg) in H₂O (50 mL) was shaken with hydrogen at 50 p.s.i. for 0.25 hrs. The solution was filtered and the filtrate concentrated by lyophilization to afford the title compound as a colorless solid with an estimated purity of 94% by HPLC. HPLC: rt 12.22 mins (Waters C₁₈ radial pak cartridge); flow rate 1mL/min. of 98% pump A (0.05 M of pH 5 ammonium phosphate buffer), 2% pump B (80% CH₃CN-20%H₂O).

30 ¹H NMR (360 MHz, D₂O) δ 8.03 (d, 1H), 6.09 (d, 1H), 5.02 (m, 1H), 4.08 (m, 1H), 3.56 (m, 2H), 2.32 (m, 1H), 2.15 (m, 1H), 2.00 (m, 1H), 1.75 (s, 3H).

35 **EXAMPLE N: Trans-cyclopent-2-ene-1,4-diol.**

Trans-2-phenylthio-3-cyclopenten-1-ol(1.21 g, 6.3 mmol) was dissolved in C₂Cl₂ (8 mL) and cooled to 0 °C in an ice bath under nitrogen. meta-Chloroperbenzoic acid (1g, 5.9mmol) was added in small batches. An exothermic reaction occurred. The reaction mixture was left to stir at room temperature for 3 hrs, and then filtered and concentrated to give the sulfoxide trans-2-phenylsulfinyl-3-cyclopenten-1-ol as a pale yellow solid. The sulphoxide was used directly without further purification. The sulphoxide was dissolved in methanol (5 mL) and trimethyl phosphite (1.17 g; 9.4 mmol) and the reaction mixture heated to reflux overnight under nitrogen. The reaction mixture was concentrated and then flash chromatographed to give the trans diol as a colorless oil. (240 mgs, 40% overall). ¹H NMR (360 MHz, CDCl₃) δ 2.1 (m, 2H CH₂); 5.0 (m, 2H, CHO); 6.05 (m, 2H, CH=CH). ¹³C NMR(50.03 MHz, CDCl₃) 44.28 (CH₂); 76.99 (CHOH); 137.20 (CH=CH).

50 **EXAMPLE O: Trans-1-diethylphosphonomethoxy-2-(phenylthio)cyclopent-3-ene.**

Sodium hydride (60%) (460 mgs; 11.5 mmol) was added to a dry three neck 100 ml round bottom flask equipped with a nitrogen inlet and magnetic stirrer. The hydride was washed with hexane (2 x 25 mL) and ether (2 x 25 mL), and the solvent removed by syringe after each washing. After the last wash the last traces of ether were removed on the pump. THF (10 mL) was added to the sodium hydride and the suspension was cooled in a ice-salt bath under a nitrogen atmosphere. Trans-2-phenylthiocyclopent-3-en-1-ol (2g, 10.5 mmol) in THF (5mL) was then added dropwise over 5 mins; hydrogen evolution was observed. Once all the alcohol had been added, the reaction mixture was left to stir at 0 °C for 1 hr and at ambient

temperature for 1 hr. The reaction mixture became very dark in color during this time.

The reaction mixture was then cooled in a ice-salt bath again and a solution of trifluoromethanesulphonyloxymethyldiethylphosphonate (3.43 g, 11.4 mmol) in THF (10 mL) was slowly added dropwise. After addition, the reaction mixture was stirred at 0 °C for 1 hr. A further 0.5 equivalents of triflate in THF were added and the reaction mixture then allowed to stir at ambient temperature for 0.5 hr. Methanol (3 mL) was added followed by ethyl acetate (50 mL). The organic phase was washed with brine, dil. sodium bicarbonate, water, brine and then dried over MgSO₄. The dried solution was filtered and concentrated to leave a clear dark brown oil. The product was purified by flash column chromatography with 2% MeOH/98% CH₂Cl₂ as eluent. to leave a colorless oil (2.33 g; 66%). ¹H NMR (360 MHz, CDCl₃): δ 7.81-7.43 (m, 5H), 5.78 (b, 1H), 5.69 (q, 1H), 4.02-4.15 (m, 4H), 3.51-3.65 (m, 2H), 2.61-2.67 (m, 1H), 2.37 (d, 1H), 1.24-1.32 (m, 6H). ¹³C NMR (50.03 MHz, CDCl₃) 131.97, 129.64, 128.93, 127.16, 126.78, 87.51 and 87.26, 64.65 and 61.29, 62.51 and 62.38, 58.07, 38.17 and 16.55 and 16.42.

EXAMPLE P: Trans-1-diethylphosphonomethoxy-2-(phenylsulfinyl)-cyclopent-3-ene.

The sulfide (2.1 g; 6.1 mmol) was dissolved in CH₂Cl₂ (30 mL), under nitrogen, and cooled to 0 °C. A solution of mCPBA (1.2 g; 7 mmol) in CH₂Cl₂ (10 mL) was then added dropwise. The reaction mixture was then stirred at 0 °C for 1.5 hrs. The reaction mixture was concentrated and flash chromatographed using 5% MeOH/95% CH₂Cl₂ as eluent. The product was a white solid (2.1 g; 95%).

EXAMPLE Q: Trans-1-diethylphosphonomethoxy-cyclopent-2-en-4-ol.

The sulphoxide (1 g, 2.7 mmol) was dissolved in MeOH (3 mL) and trimethylphosphite (0.7 g, 5.6 mmol) added under a nitrogen atmosphere. The reaction mixture was heated to reflux for 4 hrs and then allowed to cool. A saturated solution of NaHCO₃ (3 mL) was added and the mixture stirred for ten minutes. The reaction mixture was then extracted with ethyl acetate (3 x 25 mL) and the organic washings dried (MgSO₄). The dried solution was filtered and concentrated to give a pale yellow oil. The desired product was obtained as a colorless oil (220 mg, 32 %) after flash chromatography of the yellow oil with 5% MeOH/95% CH₂Cl₂ eluent mixture. ¹H NMR (360 MHz; CDCl₃): 6.05-6.15 (m, 1H), 5.85-5.95 (m, 1H), 4.93-4.96 (m, 1H), 4.77-4.80 (m, 1H), 4.05-4.14 (septet, 4H), 3.66-3.69 (dd, 2H), 2.10-2.17 (m, 1H), 1.89-1.96 (m, 1H) and 1.25-1.29 (b, 6H). ¹³C NMR (50.03 MHz; CDCl₃): 139.37, 133.11, 85.98 and 85.74, 75.71, 64.02 and 60.67, 62.45, 40.29 and 16.41.

EXAMPLE R: cis-1-Diethylphosphonomethoxy-4-chloro-cyclopent-2-ene.

Trans-1-Diethylphosphonomethoxycyclopent-2-en-4-ol (380 mg, 1.52 mmol) was dissolved in CH₂Cl₂ (5 mL) and the solution was cooled in an ice bath under nitrogen. Triethylamine (168 mg, 1.68 mmol) was added by syringe followed by dropwise addition of a solution of toluenesulphonyl chloride (320 mg, 1.68 mmol) in CH₂Cl₂ (1 mL). A catalytic amount of DMAP was also added and then the reaction mixture left to stir overnight. Concentrate to leave a pale yellow oil which was purified by flash column chromatography. The chloride was isolated as a colorless oil (88 mg, 21%), along with a substantial amount of starting material (220 mg, 58%). ¹H NMR (360 MHz, CDCl₃): 6.00-6.08 (m, 2H), 4.75-4.78 (m, 1H), 4.66-4.69 (m, 1H), 4.08-4.17 (m, 4H), 3.69-3.76 (m, 2H), 2.79-2.88 (quintet, 1H), 2.02-2.08 (dr, 1H, 1.29-1.39 (d, 6H).

EXAMPLE S: cis-1-Diethylphosphonomethoxy-4-chlorocyclopent-2-ene.

Trans-4-diethylphosphonomethoxycyclopent-2-en-4-ol (220 mg, 0.88 mmol) was dissolved in CH₂Cl₂ (2 mL) and cooled to 0 °C under nitrogen. Triethylamine (192 mg, 1.92 mmol) was added followed by methanesulphonyl chloride (220 mg, 1.92 mmol) and the reaction mixture left to stir for 0.5 hrs at 0 °C. The reaction mixture was allowed to warm to room temperature and MeOH was added. The aqueous solution was diluted with CH₂Cl₂ (10 mL) and washed with water; saturated NaHCO₃ and brine. The solution was dried (MgSO₄), filtered, concentrated and then purified by flash column chromatography with 5% MeOH/95% CH₂Cl₂ (144 mg, 62 %).

EXAMPLE T: (±)-9-(4-β-Diethylphosphonomethoxycyclopent-2-en-1-β-yl)adenine.

Adenine (235 mg, 1.74 mmol) was added to a suspension of sodium hydride (0.045g, 1.88 mmol) in DMF (15 mL) under a nitrogen atmosphere. The reaction mixture was warmed to 60 °C for 1 hr to form a thick, viscous white suspension. The reaction was then allowed to cool to room temperature and a suspension of sodium bromide (0.18 g, 1.74 mmol) and cis-1-diethylphosphonomethoxy-4-chlorocyclopent-2-ene (0.45 g; 1.68 mmol) added. The reactants were warmed to 60 °C under a nitrogen atmosphere for 2 hours.

The reaction mixture was allowed to cool and then concentrated in vacuo. The residue was dissolved in ethyl acetate (50 mL) and then washed with water and dilute hydrochloric acid (10%). The organic phase was then dried (Na₂SO₄). The solution was filtered and concentrated to leave a thick oil (300 mg). The product contained both the alpha and beta anomers from the condensation reaction in a 1:1 ratio determined by ¹H NMR. These two anomers were separated on an IBM instruments ¹⁸C semi-preparative column using 35% methanol:65% ammonium acetate as eluent (adjusted to pH 7). The undesired product (±)-9-(4-β-diethylphosphonomethoxycyclopent-2-ene-1-α-yl) adenine elutes first as a white solid. Analysis: C₁₅H₂₂N₅O₄P.O.SH₂O (calc) C: 47.86, H: 5.90, N: 18.64; (found) C: 48.23, H 5.99, N, 18.64. ¹H NMR (200 MHz; CDCl₃): 8.4 (s, 1H); 7.65(S,1H); 7.25 (s, 1H), 6.4-6.5 (m, 1H), 6.2-6.25 (m, 1H), 5.8-5.9 (m, 1H), 5.0-5.1 (m, 1H), 4.15-4.25 (m, 4H), 3.75-3.85 (m, 2H), 2.55-2.7 (m, 1H), 2.25-2.4 (m, 1H) and 1.25-1.4 (t, 6H). ¹³C NMR (90.53 MHz, CDCl₃): 155.49, 152.90, 149.75, 138.10, 136.54, 133.61, 119.88, 85.60 and 85.46, 63.92 and 62.00, 62.46 and 62.39, 38.94, 36.41 and 16.36 and 16.30. (±)-α-(4-β-diethylphosphonomethoxycyclopent-2-ene-1-β-yl)adenine elutes off the column second. M.p. 85-87 °C. ¹H NMR (200 MHz; CDCl₃): 8.37 (s, 1H); 6.39 (m, 1H); 6.15 (m, 1H); 5.65 (m, 1H); 4.2 (m, 4H); 3.85 (d, 2H); 2.95 (m, 1H); 2.00 (m, 1H) and 1.35 (m, 6H).

EXAMPLE U: Trans-1-Diethylphosphonomethoxy-4-phenylsulfinylcyclopent-2-ene.

Trans-1-diethylphosphonomethoxycyclopent-2-en-4-ol (0.4 g; 1.6 mmol) was dissolved in CH₂Cl₂ (6 mL) and cooled to 0 °C in an ice bath under a nitrogen atmosphere. Triethylamine (0.3 g; 2.9mmol) was then added followed by a solution of toluene sulfinyl chloride (0.4 g, 2.9 mmol) in CH₂Cl₂ (2 mL). The reaction mixture was stirred at 0 °C for 1 hr. The ice bath was removed and the reaction mixture concentrated in vacuo. The residual oil was purified by flash column chromatography with 2% methanol/98% dichloromethane as eluent. The product (0.54 g; 87%) was isolated as a colorless oil. Analysis: C₁₇H₂₅O₆PS.O.5H₂O (calc): C: 51.37, H: 6.35; (found): C: 51.66, H: 6.54. Both the ¹H NMR and ¹³C NMR show two diastereomers.

¹H NMR (360 MHz; CDCl₃): 7.55-7.59 (m, 2x2H); 7.30-7.34 (m, 2x2H), 6.09-6.15 (m, 1x2H and 1x1H), 5.70-5.73 (m, 1x1H), 5.39-5.43 (1m, 2x1H), 4.80-4.82 (m,1x1H), 4.75-4.77 (m, 1x1H), 4.06-4.21 (m, 2x4H), 3.65-3.75 (m, 2x2H), 2.41 (s, 2x3H), 2.17-2.31 (m, 1x2H), 1.89-2.16 (m, 1x2H), 1.27-1.33 (m, 2x6H). ¹³C NMR (50.03 MHz; CDCl₃): 136.5, 136.19, 135.77, 135.12, 129.67, 125.04, 85.45 and 85.19 with 85.36 and 85.11, (2x1 °C), 80.79 with 80.67 (2x1C), 64.47 and 61.15 with 64.41 and 61.07 (2x1C), 62.49 with 62.38 (2x1C), 38.68 with 38.12,(2x1C), 21.53, 16.50 with 16.39(2x1C).

EXAMPLE V: (±)-9-(4-Diethylphosphonomethoxycyclopent-2-en-1-β-yl)adenine.

Adenine (0.22 g, 1.6 mmol) was added to a suspension of sodium hydride (0.045g; 1.8 mmol) in DMF (5 mL) under nitrogen and the reaction warmed to 60 °C for 1 hr. The reaction was allowed to cool to room temperature and a solution of trans-1-diethylphosphonomethoxy-4-phenylsulfinylcyclopent-1-ene (0.6 g; 1.55 mmol) in DMF (2 mL) was then added by syringe. The reaction mixture was warmed to 70 °C overnight. The reaction was allowed to cool, filtered to remove any solids and then concentrated in vacuo. The residue was purified by flash column chromatography using 5% methanol:95% dichloromethane as eluent. The product was isolated as a white solid. M. p.: 80-91 °C

EXAMPLE W: (±)-9-(4-β-Diethylphosphonomethoxycyclopent-2-en-1-β-yl)adenine.

Trans-1-diethyl phosphonomethoxycyclopent-2-en-4-ol (0.02 g; 0.08 mmol) was dissolved in N-methyl-

pyrrolidinone (1.5 mL) under a nitrogen atmosphere. To this triphenylphosphine (0.023 g; 0.09 mmol), diethyldiazodicarboxylate (0.016 g; 0.09 mmol) and adenine (0.011 g; 0.08 mmol) were added in order and the reaction mixture left overnight. HPLC analysis shows product to be present. The reaction mixture was concentrated and then purified by flash column chromatography to give the product. This was identical to the product prepared by the method of Example V.

EXAMPLE X: (±)-9-(4-β-Hydroxycyclopent-2-en-1-β-yl)adenine

A solution of the 3,4-epoxycyclopentene (1.325 g, 15.8 mmol) in DMF (5 mL) was added dropwise to a suspension of adenine (1.74 g; 12.88 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.74 g; 0.6 mmol) in a DMF (25 mL) and THF (5 mL) mixture under a nitrogen atmosphere. The reaction mixture was stirred at ambient temperature for 1 hr and then warmed to 80-90 °C for a further 1 hr. The reaction mixture was poured onto water and then filtered. The filtrate was concentrated to leave a dark oil. The oil was purified by flash column chromatography using a methanol/dichloromethane mixture as eluent (3% MeOH/CH₂Cl₂ increasing to 5% MeOH/CH₂Cl₂). The product was isolated as a white solid. M. p. 164-167 °C. ¹H NMR: (360 MHz; CDCl₃) δ 8.26 (s, 1H), 7.83 (s, 1H), 6.33 (q, 1H), 5.80 (m, 1H), 5.26 (m, 1H), 4.84 (d, 1H), 2.97 (m, 1H), 2.23 (d, 1H). ¹³C NMR: (50.3 MHz, DMSO d₆) 156.02, 152.13, 143.62, 139.27, 139.24, 130.64, 119.03, 73.75, 57.12 and 41.08. M. S. M+H = 218.

EXAMPLE Y: (±)-9-(4-β-Diethylphosphonomethoxy-cyclopent-2-en-1-β-yl)adenine.

(±)-9-(4-β-Hydroxycyclopent-2-en-1-β-yl)adenine (3.1 g, 14 mmol) in dry THF (30 mL) was added dropwise over 0.5 hrs to a stirred suspension of sodium hydride (97%) (0.376g, 15.7 mmol) in THF (10 mL) under nitrogen. Once the addition had been completed the reaction mixture was heated to reflux for 1 hr. The solution was allowed to cool to ambient temperature and then cooled to -70 °C with a dry ice/acetone bath. A solution of trifluoromethanesulfonyloxymethyldiethyl phosphonate (4.8 g, 16.0 mmol) in THF (30 mL) was then added dropwise over 0.25 hrs. The reaction mixture was stirred at -78 °C for 2 hrs and then allowed to warm to room temperature overnight. The solution was concentrated in vacuo to leave a thick oil. This oil was purified by flash column chromatography with a methanol/dichloromethane as eluent (5% MeOH/CH₂Cl₂ increasing to a 10% MeOH/CH₂Cl₂ mixture) to give the desired product as a beige colored solid (2.0 g, 40 %). M. p. 88-90 °C. Analysis: C₁₅H₂₂N₅O₄P (calc) C: 49.05, H: 6.04, N: 19.07; (found) C: 49.19, H: 5.96, N: 19.35. ¹H NMR: (350 MHz, CDCl₃) δ 8.35 (s, 1H), 7.94 (s, 1H), 6.37 (m, 1H), 6.10 (m, 1H), 5.63 (m, 1H), 4.69 (m, 1H), 4.16 (quintet, 4H), 3.85 (m, 2H), 2.9 (m, 1H), 1.97 (d.t., 1H); 1.33 (m, 4H). ¹³C NMR (50.3 MHz, CDCl₃): 155.73, 152.89, 149.83, 139.58, 136.11, 134.02, 119.80, 84.82 (d, J = 12 Hz), 64.58 (d, J = 167 Hz), 62.90 (d, J = 2.5), 62.77 (d, J = 2.5 Hz), 36.84, 33.76 and 16.76 (d, J = 5 Hz).

EXAMPLE Z: (±)-9-(4-β-Monoethylphosphonomethoxycyclopent-2-en-1-β-yl)adenine.

(±)-9-(4-β-Diethylphosphonomethoxycyclopent-2-en-1-β-yl)adenine (0.5g; 1.35 mmol) was dissolved in a solution of 1N sodium hydroxide (13 mL) and the reaction mixture stirred at room temperature for 2 hrs. The solution was acidified with 10% aqueous hydrochloric acid and then concentrated. Residual salts were removed by reverse phase column chromatography (C18 adsorbent, elution with water) to give the product on a white solid (180 mg). M. p. = 192-205 °C. Analysis: C₁₃H₁₈N₅O₄P · 0.5H₂O (calc) C: 44.83, H: 5.50, N: 20.11; (found): C: 45.31, H: 5.37, N: 20.17. ¹H NMR (300 MHz; d₆ DMSO) 8.19 (s, 1H), 8.04 (s, 1H), 7.57 (brs, 1H), 6.30 (d, 1H), 6.18 (d, 1H), 5.50 (brs, 1H), 4.67 (brs, 1H), 3.95 (m, 2H), 3.74 (m, 2H), 2.87 (m, 1H), 1.90 (m, 1H), 1.22 (s, 3H). ¹³C NMR (75.40 MHz, d₆ DMSO) 155.65, 151.92, 149.02, 138.78, 135.45, 133.33, 116.79, 83.73 (d, J = 13 Hz), 63.29 (d, J = 161 Hz), 60.68, 56.52, 37.76 and 16.35 (d, J = 5 Hz).

EXAMPLE AA: (±)-9-(4-β-Phosphonomethoxycyclopent-2-en-1-β-yl)adenine.

Bromotrimethylsilane (2.1 g, 13.5 mmol) was added to a solution of (±)-9-(4-β-diethylphosphonomethoxycyclopent-2-en-1-β-yl)adenine (0.5 g, 1.35 mmol) in dry DMF (5 mL) at room

temperature under a nitrogen atmosphere. The reaction vessel was covered with foil. The reaction mixture was left to stir at room temperature for 4 hrs. The volatiles were then removed in vacuo to leave a thick oil. The residue was treated with water (2-3 mL) followed by acetone (2-3 mL). After standing for a few minutes a brown precipitate falls out. The precipitate was collected and crystallized from water/acetone (80 mg). M. p. 218-220 °C (dec).

Analysis: $C_{11}H_{14}N_5O_4P \cdot 0.5H_2O$ (calc): C: 41.26, H: 4.42, N: 21.87; (found): C: 41.53, H: 4.49, N: 21.57. 1H NMR (360 MHz; d_6 DMSO): 8.16 (s, 1H), 8.03 (s, 1H), 7.38 (s, 1H), 6.36 (d, 1H), 6.16 (d, 1H); 5.49 (brs, 1H), 4.66 (brs, 1H); 3.64 (d, 2H); 2.87 (m, 1H); 1.90 (d, 1H). ^{13}C NMR (75.46 MHz; d_6 DMSO): 155.62, 151.93, 149.05, 138.80, 135.54, 133.13, 118.85, 83.62 (d, $J = 5$ Hz), 64.87 (d, $J = 169$ Hz), 56.46 and 37.61.

EXAMPLE BB: (\pm)-9-(4- β -Diethylphosphonomethoxy-cyclopentan-1- β -yl)adenine.

(\pm)-9-(4- β -Diethylphosphonomethoxy-2-cyclopentane-1- β -yl)adenine (0.4 g; 1.1 mmol) was dissolved in ethanol (10 mL) and PtO_2 catalyst (20 mg) added. The reaction was stirred under a hydrogen atmosphere for 18 hrs. The reaction mixture was filtered and purified by flash column chromatography to give the product as a colorless oil (378 mg). Analysis: $C_{15}H_{24}N_5O_4P \cdot 0.5 EtOH$ (calc): C: 48.96, H: 6.95, N: 17.84; (found): C: 48.93, H: 6.83, N: 17.48. 1H NMR (200 MHz; $CDCl_3$): 8.39 (s, 1H), 8.12 (d, 1H), 6.13 (brs, 1H), 5.18 (brs, 1H), 4.2-4.35 (m, 4H), 3.90 (m, 2H), 1.8-2.62 (set of m, 6H) and 1.37 (m, 6H). ^{13}C NMR (50.3 MHz; $CDCl_3$): 155.80, 152.38, 149.48, 138.99, 110.95, 82.88 (d, $J = 13$ Hz), 62.44 (d, $J = 168$ Hz), 62.35 d, $J = 27$ Hz), 61.96, 52.21, 39.18, 31.63, 30.68 and 16.45 (d, $J = 5$ Hz).

EXAMPLE CC: (\pm)-9-4- β -Phosphonomethoxycyclopentan-1- β -yl) adenine

Bromotrimethylsilane (0.84 g; 5.5 mmol) was added to a solution of (\pm)-9-4- β -diethylphosphonomethoxycyclopentan-1- β -yl)adenine (0.2 g; 0.55 mmol) in dry DMF (2 mL) at room temperature under a nitrogen atmosphere and the reaction mixture stirred for 12 hrs. The volatiles were removed in vacuo to leave a thick oil. Water was added and the oil went into solution. Acetone was then added and a precipitate fell out of solution. The precipitate was recrystallized from water/acetone. The product was a white solid. M. p. 255 °C (dec). Analysis: $C_{11}H_{16}N_5O_4P \cdot 0.5H_2O$ (calc): C: 42.08, H: 5.15, N: 22.36; (found): C: 42.36, H: 5.15, N: 22.20. 1H NMR (200 MHz; d_6 DMSO) δ 8.25 (s, 1H), 8.19 (s, 1H), 7.2- (brs, 2H), 5.0 (m, 1H), 4.18 (m, 1H), 3.33 (d, 2H), 1.6-2.4 (m, 6H).

EXAMPLE DD: (\pm)-6-O-Benzyl-9-(4- β -hydroxycyclopent-2-en-1- β -yl)guanine

A solution of the 3,4-epoxycyclopentene (6.38 g; 77.7 mmol) in DMF (10 mL) was added dropwise over 0.66 hr to a prewarmed (67 °C) solution of 6-O-benzylguanine (12.5 g; 52.6 mmol) tetrakis-(triphenylphosphine)palladium (0) (3.0 g; 2.6 mmol) and triphenylphosphine (1.35 g; 5.51 mmol) in DMF (150 mL). Once all the epoxide had been added the reaction was left at 75 °C overnight. The reaction mixture was then allowed to cool to room temperature. The reaction was filtered and then concentrated to a yellowish oil. This oil was purified by flash column chromatography using a methanol/dichloromethane mixture as eluent (1% MeOH/ CH_2Cl_2 increasing to 10% MeOH/ CH_2Cl_2) to give the product as a white solid (13.0 g, 77 %). M. p.: 110-115 °C. Analysis: $C_{17}H_{17}N_5O_2 \cdot 0.5H_2O$ (calc): C: 61.44, H: 5.46, N: 21.08, (found) 61.32, H: 5.43, N: 19.78. 1H NMR (360 MHz; d_6 DMSO + D_2O): 7.76 (s, 1H), 7.29-7.46 (m, 5H), 6.13 (m, 1H), 5.89 (m, 1H), 5.47 (s, 1H), 5.25 (brs, 1H), 4.66 (brs, 1H), 2.69-2.85 (m, 1H) and 1.55-1.61 (m, 1H). ^{13}C NMR (50.30 MHz; $CDCl_3$): 161.15, 158.29, 152.50, 139.49, 139.38, 136.18, 129.89, 128.30, 128.16, 127.95, 116.77, 75.04, 68.01, 59.53 and 39.37.

EXAMPLE EE: (\pm)-N2-monomethoxytrityl-6-O-Benzyl-9-(4- β -hydroxycyclopent-2-en-1- β -yl)guanine.

(\pm)-6-O-Benzyl-9-(4- β -hydroxycyclopent-2-en-1- β -yl)guanine (12.65 g; 39.12 mmol) was dissolved in DMF (200 mL) and anisylchlorodiphenylmethane (14.53 g; 46.94 mmol); triethylamine (9.8 g; 13.5 mL; 97.03 mmol) and dimethylaminopyridine (DMAP) (100 mg) were then added in turn. Once all the reactants had been added the reaction was stirred at room temperature overnight. The DMF was then removed in vacuo

to leave a pale yellow oil which was purified by flash column chromatography with ethyl acetate/ hexane as eluent (10:1 EtOAc/ Hexane). The desired product was isolated as a colorless oil which became a foam on drying (21.5 g, 92 %). M.p. $^{\circ}\text{C}$. Analysis $\text{C}_{17}\text{H}_{33}\text{N}_5\text{O}_3 \cdot 1.0\text{H}_2\text{O}$: (calc) C: 72.43, H: 5.38, N: 11.41, (found) C: 72.43, H: 5.73, N: 12.06. ^1H NMR (360 MHz; CDCl_3) δ 7.99 (s, 1H), 7.36 (s, 1H), 7.14-7.29 (m, 17H), 6.73 (d, 2H), 6.23 (d, 1H), 5.77 (m, 1H), 5.10 (d, 1H), 4.76 (d, 1H), 4.70 (s, 2H), 3.79 (s, 3H), 2.79-2.80 (m, 1H), 2.06 (d, 1H).

EXAMPLE FF: (\pm) - N2-monomethoxytrityl-6-O-benzyl-9-(4- β -diethylphosphonylmethoxycyclopent-2-en-1- β -yl)guanine.

(\pm) - N2-monomethoxytrityl-6-O-benzyl-9-(4- β -hydroxycyclopent-2-en-1- β -yl)guanine (8.3 g; 13.93 mmol) was dissolved in DMF (90 mL) and stirred under argon. Sodium hydride (835 %; 52 mg; 27.86 mmol) was then added and the resulting slurry stirred at room temperature for 2.5 hr during which time the reaction mixture became dark brown. Diethyl tosyloxymethylphosphonate (6.7 g; 20.90 mmol) was introduced into the suspension via a syringe. The reaction mixture was stirred at room temperature for 20 hr. during which time it became homogeneous. Ethanol (10 mL) was added and the reaction stirred for a further 0.3 hr. The solution was concentrated in vacuo and the residue flash chromatographed on silica with ethanol/ ethyl acetate (2 -10 %) as eluent. The desired fractions were collected to afford the product (5.7 g; 57 %) as an off white foam after drying in vacuo. Analysis $\text{C}_{42}\text{H}_{44}\text{N}_5\text{O}_6\text{P} \cdot 0.5\text{H}_2\text{O}$: (calc) C: 66.84, H: 6.01, N: 9.28, (found) C: 67.09, H: 6.10, N: 9.01. ^1H NMR (300 MHz, d_6 DMSO) 7.56 (s, 1H), 7.45 - 7.13 (m, 17H), 6.81 (d, 2H), 6.26 (br s, 1H), 6.01 (br s, 1H), 5.03 (br m, 3H, H_4' plus CH_2), 4.56 (br s, 1H), 4.05 - 3.95 (m, 4H), 3.85 (d, $J = 8$ Hz, 2H), 3.68 (s, 3H), 2.60 (m, 1H), 1.70 (m, 1H), 1.18 (m, 6H).

EXAMPLE GG: (\pm) 9-(4- β -Diethylphosphonylmethoxycyclopent-2-en-1- β -yl)guanine


The product from example FF (3.65 g, 2.68 mmol) was dissolved in glacial acetic acid (90 mL), and the resulting yellow solution was heated on a steam bath with occasional swirling for 3 hr. The acetic acid was removed in vacuo and residue flash chromatographed on silica using methanol/dichloromethane (5 - 10 %) as eluent. The desired product was obtained as a white solid (3.65 g, 68 %). M. P. $^{\circ}\text{C}$. Analysis $\text{C}_{15}\text{H}_{22}\text{N}_5\text{O}_5\text{P}$: (calc) C: 47.00, H: 5.79, N: 18.27, (found) C: 46.82, H: 6.00, N: 17.92. ^1H NMR (360 MHz, d_6 DMSO) 7.31 (s, 1H), 6.27 (s, 2H), 6.16 (m, 1H), 5.96 (m, 1H), 5.05 (m, 1H), 4.43 (m, 1H), 3.85 (m, 4H), 3.72 (d, 2H), 2.59 (m, 1H), 1.64 (m, 1H), 1.05 (m, 6H). ^{13}C NMR (50 MHz; d_6 DMSO)-156.73, 153.46, 150.53, 135.16, 134.93, 133.86, 116.54, 83.83 (d, $J = 13$ Hz), 61.89 (d, $J = 163$ Hz), 61.73, 61.61, 56.00, 37.60, 16.20 (d, $J = 6$ Hz).

EXAMPLE HH: (\pm) 9-(4- β -Dihydroxyphosphonomethoxycyclopent-2-en-1- β -yl) guanine.


(\pm) 9-(4- β -Diethylphosphonomethoxycyclopent-2-en-1- β -yl)guanine (1.15 g; 3.0 mmol) was placed in dry DMF (20 mL) to give a white slurry. Bromotrimethylsilane (3.9 mL) was added by syringe and the reaction mixture which immediately became homogeneous was stirred at ambient temperature for 20 hr. under argon. The yellow solution was concentrated in vacuo to remove the solvent residue (1 g) was dried under vacuum for 3 hr. The resultant foam was dissolved in H_2O (5 mL) and stirred for 0.5 hr. Acetone was then added to the reaction mixture and a white precipitate came out of solution. The reaction was left stirring for 18 hr. The solution was filtered and the white precipitate collected. The solid was then recrystallised from water to afford the product as a white crystalline solid (860 mg, 88 %) M. p. $^{\circ}\text{C}$. Analysis $\text{C}_{11}\text{H}_{14}\text{N}_5\text{O}_5\text{P} \cdot 1.0\text{H}_2\text{O}$: (calc) C: 38.27, H: 4.68, N: 20.29, (found) C: 38.10, H: 4.76, N: 20.24. ^1H NMR (360 MHz, d_6 DMSO) 7.58 (s, 1H), 6.45 (s, 2H), 6.29 (m, 1H), 6.06 (m, 1H), 5.21 (br s, 1H), 4.60 (m, 1H), 3.62 (m, 2H), 2.77 (m, 1H), 1.78 (m, 1H). ^{13}C NMR (75 MHz, d_6 DMSO) 156.57, 153.36, 150.45, 135.41, 133.26, 116.23, 83.57, 64.18 (d, $J = 161$ Hz), 56.07, 37.64.

Claims

1. A 1-B-4-phosponylmethoxycyclopentane having Formula I or Formula II



I



II

wherein

R^1 and R^2

are independently hydrogen, hydroxy, chlorine, bromine, or an organic substituent having 1 to 5 carbon atoms and selected from carbacyloxy, alkoxy, alkylthio, amino, alkylamino and dialkylamino,

R^3 and R^4

are independently hydrogen, or organic phosphonic ester substituents having 1 to 12 carbon atoms and selected from alkyl, alkenyl, aryl, and aralkyl,

B is a heterocyclic group having at least one nitrogen heteroatom and up to three additional heteroatoms selected from nitrogen, oxygen and sulfur, said heterocyclic group being attached through a nitrogen heteroatom thereof,

and the pharmaceutically acceptable acid addition, metal, and amine salts thereof.

2. The compound of Claim 1 wherein B is a heterocyclic group selected from purine, pyrimidine, azapurine, triazine, deazapurine, pyridine, and triazole, said heterocyclic group being substituted with from 1 to 3 substituents independently selected from oxo, hydroxy, amino, fluoro, chloro, bromo, iodo, alkyl having 1 to 3 carbon atoms, alkenyl having 2 to 3 carbon atoms, haloalkenyl having 2 to 3 carbon atoms, alkoxy having 1 to 3 carbon atoms, and alkylthiol having 1 to 3 carbon atoms.

3. The compound of Claim 2 wherein B is a heterocyclic group selected from, monosubstituted purine, or disubstituted purine.

4. The compound of Claim 2 wherein B is a heterocyclic group selected from monosubstituted pyrimidine, disubstituted pyrimidine, or trisubstituted pyrimidine.

5. The compound of Claim 1 having the $1\beta,4\beta$ -conformation.

6. The compounds of Claim 1:

1-[(1 $\beta,4\beta$)-4-(dihydroxyphosphonyl)methoxycyclopent-2-en-1-yl]thymine,

1-[(1 $\beta,4\beta$)-4-(dihydroxyphosphonyl)methoxycyclopent-2-en-1-yl]cytosine,

[(1 $\beta,4\beta$)-4-(diethoxyphosphonyl)methoxycyclopent-2-en-1-yl]adenine,


9-[(1 $\beta,4\beta$)-4-(ethoxyhydroxyphosphonyl)methoxycyclopent-2-en-1-yl]adenine,

9-[(1 $\beta,4\beta$)-4-(dihydroxyphosphonyl)methoxycyclopent-2-en-1-yl]adenine,

9-[(1 $\beta,4\beta$)-4-(diethoxyphosphonyl)methoxycyclopentan-1-yl]adenine,


9-[(1 $\beta,4\beta$)-4-(dihydroxyphosphonyl)methoxycyclopentan-1-yl]adenine.

7. The compound of Claim 1 having the formula




wherein R^3 and R^4 have the same definitions as given in Claim 1, and P is hydrogen or an amino protecting group.

8. The compound of Claim 1 having the formula




wherein R^3 and R^4 have the same definitions as in Claim 1 and P is hydrogen or an amino protecting group.

9. The compound of Claim 1 having the formula




wherein R^3 and R^4 have the same definitions as in Claim 1, and P and P' are hydrogen or respectively amino and hydroxy protecting groups.

10. The process for preparing the compound of Claim 1, having Formula I which comprises etherifying a cyclopentenol derivative of Formula IV




IV

with a phosphonylmethylating agent of Formula V



V

or aminating a phosphonylmethoxy cyclopentenol derivative of Formula VI



VI

with a nitrogen heterocycle of the formula BH, wherein R^3 and R^4 are organic phosphonic ester substituents as defined in Claim 1, B is a heterocyclic group as defined in Claim 1, and the group L in Formulas V and VI is a leaving group.

11. The process for preparing the compound of Claim 1 having Formula II wherein R^1 and R^2 are each

hydrogen, which comprises contacting the compound of Claim 1 having Formula I with hydrogen in the presence of a catalyst under reaction conditions appropriate for reducing a cyclopentene to a cyclopentane.

12. The process for producing a monoester phosphonic acid of Claim 1 having Formula I or Formula II wherein one of R^3 and R^4 is hydrogen and the other is an organic phosphonic ester substituent, which
5 comprises contacting a compound of Formula I or Formula II wherein R^3 and R^4 are each organic phosphonic ester substituents with water in the presence of an alkali metal base at room temperature.

13. The process for preparing the phosphonic acid of Claim 1 having Formula I or Formula II wherein each of R^3 and R^4 is hydrogen which comprises contacting a compound having Formula I or Formula II wherein one or both of R^3 and R^4 is an organic phosphonic ester substituent other than hydrogen with
10 trimethylsilyl bromide under reaction conditions.

14. A pharmaceutical composition comprising at least one compound according to anyone of claims 1 to 9, optionally in combination with pharmaceutically acceptable carriers and/or excipients.

15. A process for preparing a pharmaceutical composition of claim 14 which comprises providing at least one compound of claims 1 to 9 in a form suitable for administration, optionally incorporated into a
15 pharmaceutically acceptable carrier and/or excipient.

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 89 12 1085

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.5)
A	EP-A-0 015 584 (GAURI K.K.) * Claims * ----	1,10,14	C 07 F 9/651 A 61 K 31/675 C 07 F 9/656
A	COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol. 52, no. 10, October 1987, pages 2572-2588, Academia Nakladatelství Československé Akademie Ved; I. ROSENBERG et al.: "Synthesis of phosphonylmethyl analogues of diribonucleoside monophosphates containing modified internucleotide bond" * Whole document * -----	1,10,14	
			TECHNICAL FIELDS SEARCHED (Int. CL.5)
			C 07 F 9/00 A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 08-02-1990	Examiner OUSSET J-B.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document			